Reviewed listing: NASDAQ:BCRX · Analysis dated Oct 13, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
BioCryst develops and sells medicines for rare diseases; its leading product, ORLADEYO, is taken daily to prevent swelling attacks in an inherited disease. Navenibart is intended to complement the offering with a long-acting injection, but it is still in development.
What supports the business?
The established drug business is a positive: second-quarter ORLADEYO revenue grew 2026 by about 10%, excluding the sold European business. Even after simply subtracting the new revenue from licensing rights, the ongoing business remains profitable, but reported earnings cannot be fully repeated.
What could improve?
The child formulation of ORLADEYO has been shipping since 3. August 2026 and could reach new patients; the company expects pivotal study results for navenibart in the third quarter of 2027. Both offer opportunities but guarantee neither additional profits nor a rise in the share price.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 8.36 USD, an attractive share price is not convincingly established; further growth and successful new drugs could help the stock, but their economic contribution remains uncertain. The model calculation shows what assumptions the price requires, but does not prove that the stock is too expensive.
What is the main risk?
The main risks are dependence on ORLADEYO, competing drugs, unsuccessful drug trials, and financing the acquisition of Astria. The large half-year loss arose mainly from a one-time expense for this acquisition, which nevertheless cost real money and required additional financing.
What is the overall assessment?
Watch: a viable product business and plausible expansion opportunities, but at 8.36 USD there is no sufficiently well-supported positive price assessment. The earnings jumps include significant special items. The conditional valuation model establishes neither that the stock is cheap nor that it is overvalued.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com
- Original source 2 · data.sec.gov
- Original source 3 · data.sec.gov
- Original source 4 · www.sec.gov · Feb 26, 2026
- Original source 5 · ir.biocryst.com · Feb 26, 2026
- Original source 6 · www.sec.gov · Aug 05, 2026
- Original source 7 · ir.biocryst.com · Aug 05, 2026
- Original source 8 · ir.biocryst.com